Free Trial
CVE:AQS

Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis

C$0.01
-0.01 (-33.33%)
(As of 10/15/2024)

About Aequus Pharmaceuticals Stock (CVE:AQS)

Key Stats

Today's Range
C$0.01
C$0.01
50-Day Range
C$0.01
C$0.03
52-Week Range
C$0.01
C$0.05
Volume
9,705 shs
Average Volume
179,324 shs
Market Capitalization
C$1.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Stock News Headlines

Aequus Pharmaceuticals Inc. (AQSZF)
Aequus Pharmaceuticals Inc (AQS)
New gold frenzy underway
Gold: Now legal tender Most Americans missed this big story, but 1 in 5 states have now made gold and silver coins legal tender. It's just one reason why so many predict gold will soon hit $5,000. And why you need to check out this $6 strategy for gold immediately.
AQS:CA Aequus Pharmaceuticals Inc.
See More Headlines

AQS Stock Analysis - Frequently Asked Questions

Aequus Pharmaceuticals' stock was trading at C$0.03 at the beginning of the year. Since then, AQS stock has decreased by 60.0% and is now trading at C$0.01.
View the best growth stocks for 2024 here
.

Aequus Pharmaceuticals Inc. (CVE:AQS) issued its earnings results on Thursday, August, 29th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.16 million for the quarter.

Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Acorn Energy (ACFN), Crown Castle (CCI), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Rogers (ROG).

Company Calendar

Last Earnings
8/29/2024
Today
10/21/2024
Next Earnings (Estimated)
12/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
C$-2,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.17 million
Cash Flow
C$0.00 per share
Book Value
C($0.04) per share

Miscellaneous

Free Float
N/A
Market Cap
C$1.33 million
Optionable
Not Optionable
Beta
-0.02
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (CVE:AQS) was last updated on 10/21/2024 by MarketBeat.com Staff
From Our Partners